Description
Tratamiento de esclerosis múltiple remitente-recurrente (EMRR)
Monitorear parámetros hematológicos durante el tratamiento
HEMLIBRA® 150 mg/mL es un medicamento anticuerpo monoclonal cuyo principio activo es Emicizumab
KitosCell-Q®
5 MG | Comprimidos | Caja con 30 CPR | Novartis
TRONIUM IV INY CON DILUYENT 40MG - SOL 1 PRESERVATIVOS Tratamiento de esclerosis múltiple remitente-recurrentePRINCIPIO ACTIVO: ESOMEPRAZOL
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
You may also like
recommand products
